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The first crystal structures of the class D -lactamases OXA-181 and OXA-245
were determined to 2.05 and 2.20 Å resolution, respectively; in addition, the
structure of a new crystal form of OXA-163 was resolved to 2.07 Å resolution.
All of these enzymes are OXA-48-like and have been isolated from different
clinical Klebsiella pneumoniae strains and also from other human pathogens
such as Pseudomonas aeruginosa and Escherichia coli. Here, enzyme kinetics
and thermostability studies are presented, and the new crystal structures are
used to explain the observed variations. OXA-245 had the highest melting point
(Tm = 55.8
C), as determined by differential scanning calorimetry, compared
with OXA-163 (Tm = 49.4
C) and OXA-181 (Tm = 52.6C). The differences
could be explained by the loss of two salt bridges in OXA-163, and an overall
decrease in the polarity of the surface of OXA-181 compared with OXA-245.
1. Introduction
After 70 years, penicillin and other -lactam antibiotics are
still the best weapons for fighting bacterial infections;
however, the rise of bacterial strains resistant to -lactam
antibiotics threatens to make them obsolete (O’Neill, 2016;
Bush & Macielag, 2010). The most common mechanisms for
bacteria to become resistant to -lactam antibiotics is the
uptake of foreign genetic material encoding -lactamases:
enzymes that break down the central -lactam ring of these
antibiotics, rendering them inactive (Bush & Bradford, 2016).
To date (June 2017), over 2600 -lactamases have been
described (Bush, 2013a; http://bldb.eu). Based on their genetic
sequence and structural motifs, -lactamases can be grouped
into four classes: A–D (Hall & Barlow, 2005; Bush, 2013b).
The largest class, with more than 500 members, is class D. This
class is often referred to as the oxacillinases (OXAs) owing to
their preferential hydrolysis of oxacillin. Typically, this class
has not been considered to be as threatening as the other
classes. Still, it contains members which may inactivate the
entire spectrum of -lactam antibiotics (Leonard et al., 2013;
Evans & Amyes, 2014; Docquier & Mangani, 2016).
One of the most geographically widespread members of the
class D -lactamases is OXA-48 (Vallejo et al., 2016). OXA-48
and the increasing number of OXA-48-like variants have been
called the ‘phantom menace’ owing to their broad substrate
specificity and the difficulties in identifying bacteria expressing
OXA-48-like enzymes (Poirel et al., 2012). The OXA-48-like
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-lactamases OXA-163, OXA-181 and OXA-245 have all
been identified in Klebsiella pneumoniae (Potron, Nordmann
et al., 2011; Oteo et al., 2013). Although K. pneumoniae is most
commonly found in soil and water, it frequently causes
infections in immunocompromised individuals and has been
connected to outbreaks of nosocomial infections (Podschun &
Ullmann, 1998; Paczosa & Mecsas, 2016; Navon-Venezia et al.,
2017). OXA-163 and OXA-181 have also been identified in
other human pathogens such as Escherichia coli (McGann et
al., 2015; Stoesser et al., 2016), and OXA-181 has been iden-
tified in Pseudomonas aeruginosa strains (Meunier et al.,
2016). OXA-181 is reported to originate from a Shewanella
xiamenensis chromosomal -lactamase (Potron, Poirel et al.,
2011) and OXA-163 also appears to originate from Shewa-
nella. spp, while OXA-245 appears from random mutations of
the OXA-48 gene in K. pneumoniae strains (Pérez-Vázquez et
al., 2016). OXA-163 was first identified in Argentina (Poirel et
al., 2011), but has also been observed in Egypt (Abdelaziz et
al., 2012). OXA-181 has been identified all over the world
(Potron, Nordmann et al., 2011; Samuelsen et al., 2013; Rojas et
al., 2017). The strain responsible for OXA-245, however,
appears to be limited to Spain (Pérez-Vázquez et al., 2016).
The sequence identities compared with OXA-48 are 98.0% for
OXA-163, 98.4% for OXA-181 and 99.6% for OXA-245,
using Gly22 (left after TEV cleavage) and the periplasmic part
(Lys23–Pro256) for all four enzymes.
While class D -lactamases are a diverse class with respect
to protein sequence, their tertiary structures are highly
conserved. All known structures of OXAs share an -fold
and many form dimers in solution (Docquier et al., 2009;
Paetzel et al., 2000; Dale & Smith, 1976). The active site of
OXAs is made up of three conserved motifs, 70STFK73,
118SVV120 and 208KTG210, and each monomer has an inde-
pendent active site. The serine in the STFK motif has been
identified as the nucleophile that is responsible for the
formation of the acyl-complex with -lactam antibiotics
(Paetzel et al., 2000), while the lysine in the same motif has a
conserved post-translational carboxylation that is important
for deacetylation (Schneider et al., 2009). The structures of the
homologues OXA-48, OXA-163, OXA-232 and OXA-405
have been published (Docquier et al., 2009; Stojanoski et al.,
2015). In this study, we wanted to thoroughly characterize the
antibiotic-resistance enzymes OXA-163, OXA-181 and OXA-
245 by comparing their thermostabilities, hydrolytic properties
and crystal structures with those of the OXA-48 enzyme with
worldwide spread.
2. Materials and methods
2.1. Cloning of OXA-181 and OXA-245 and recombinant
macromolecule production
Genes encoding OXA-181 and OXA-245 were amplified
from clinical isolates and cloned into a pDEST-17 vector
using exponential megaprimer cloning (EMP) as described
previously (Lund et al., 2014, 2016). Two gene constructs were
made for both OXA-181 and OXA-245, in which one gene
construct encoded the full-length gene with the signal peptide,
thus including residues 1–265 (nOXA-181 and nOXA-245),
and a second gene construct encoded a truncated gene with a
hexahistidine (His) tag and a TEV protease site followed by
residues 23–265 (tOXA-181 and tOXA-245).
Synthetic DNA encoding an OXA-163 construct with a
TEV protease site (ENLYFQG) followed by residues Lys23–
Pro265 (tOXA-163), codon-optimized for expression in
E. coli, was purchased from Life Technologies (Thermo Fisher
Scientific). The DNA was inserted in pDEST17, which carries
an N-terminal His tag. The primers and strains used in this
study are described in Supplementary Table S1.
All enzymes were produced recombinantly. tOXA-181 and
tOXA-163 were produced in E. coli BL21 (DE3) pLysS cells in
Terrific Broth medium (TB) with 100 mg ml1 ampicillin and
34 mg ml1 chloramphenicol, the cells were induced by 0.4 mM
isopropyl -d-1-thiogalactopyranoside (VWR) at log phase
and expression was continued at 20C for 16 h. nOXA-181,
nOXA-245 and tOXA-245 were produced in E. coli BL21 Star
(DE3) pRARE cells in ZYP5052 autoinduction medium at
310 K (37C) for 3–4 h and then left at 293 K (20C) for 16 h.
Recombinant nOXA-181 and nOXA-245 were isolated
from the periplasm after lysozyme treatment and were puri-
fied by two steps using an anion exchanger (Giuliani et al.,
2005). Contaminants were bound on an anion-exchange Q
Sepharose column at 277 K (4C) equilibrated with 25 mM
bis-tris propane pH 7.2. The pH of the running buffer was
adjusted to pH 9.5 before applying a pH gradient from pH 9.5
to 6.5 with 25 mM bis-tris propane. A cation-exchange column
(HiTrap SP) was used for polishing with a gradient from pH
6.5 (25 mM HEPES) to pH 8.5 (25 mM HEPES) with 150 mM
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Table 1
Crystallization conditions for tOXA-163, tOXA-181 and tOXA-245.
tOXA-163 tOXA-181 tOXA-245
Method Vapour diffusion
Plate type Hampton Research VDX 24-well plate with sealant
Temperature (K) 298
Protein concentration (mg ml1) 9 11 3
Buffer composition of protein solution 50 mM HEPES pH 7.2, 50 mM K2SO4 50 mM Tris pH 7.2, 50 mM K2SO4 25 mM HEPES pH 7.5
Composition of reservoir solution 0.1 M Tris pH 9.0, 28% PEG 500 0.1 M Tris pH 7.0, 0.2 M ammonium sulfate,
20.5% PEG MME 5000
0.1 M HEPES pH 7.0,
10% PEG 6000
Drop volume (ml) 2 1 2
Protein:reservoir ratio 3:20 1:1 1:1
Reservoir volume (ml) 1000 800 500
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potassium sulfate. Recombinant tOXA-163, tOXA-181 and
tOXA-245 were isolated from sonicated and clarified samples,
and were first purified by nickel immobilized metal-affinity
chromatography (Ni-IMAC) at 277 K (4C) with a 0–500 mM
imidazole gradient also including 25 mM HEPES pH 6.5 and
50 mM potassium sulfate (Lund et al., 2016). The semi-pure
enzyme extract was then cleaved using in-house-purified TEV
protease (with L56V, S135G, S219N, T17S, N68D and I77V
mutations; Leiros et al., 2014) to remove the His tag, and the
cleaved protein was again purified using Ni-IMAC, with the
cleaved protein eluting in the flowthrough (Lund et al., 2016;
Leiros et al., 2014). The last polishing step was a cation-
exchange column as described for the enzyme isolated from
the periplasm. Finally, the TEV constructs were dialysed in
different storage buffers (Table 1), and nOXA-181 and
nOXA245 were dialysed in 50 mM HEPES pH 7.2, 50 mM
potassium sulfate. The proteins were concentrated using
Centriprep centrifugal filters (Merck) and the protein
concentrations were measured using the OD280, molecular
weights (MW) and extinction coefficients for each gene
construct.
2.2. Enzyme kinetics of nOXA-181 and nOXA-245
Enzyme characterization and determination of the kinetic
parameters were carried out as previously described for
nOXA-48 (Antunes et al., 2014; Lund et al., 2016). Substrate
hydrolysis was measured by monitoring the UV absorbance
for ampicillin ("235 nm = 820 M1 cm1, 1–100 mM,
100 pM nOXA-181/nOXA-245); ceftazidime ("260 nm =
9000 M1 cm1, 18–300 mM, 5 nM nOXA-181/10 nM
nOXA-245); ertapenem ("300 nm = 6920 M1 cm1, 10–
1000 mM, 5 nM nOXA-181/nOXA-245); imipenem ("300 nm =
9000 M1 cm1, 1–100 mM, 5 nM nOXA-181/nOXA-245)
and meropenem ("300 nm = 6500 M1 cm1, 0.02–50 mM,
5 nM nOXA-181/2 nM OXA-245). A SpectraMax M2e
(Molecular Devices, Sunnyvale, California, USA) plate reader
at 25C and nonlinear regression using GraphPad Prism 6
(GraphPad Software) were used to determine kcat and Km with
substrate-hydrolysis velocities from the linear phase of the
reaction course.
2.3. Thermostability analysis by differential scanning
calorimetry (DSC)
Purified tOXA-48 (Lund et al., 2016), tOXA-163, tOXA-
181 and tOXA-245 were dialyzed against 50 mM HEPES pH
7.0 supplemented with 50 mM potassium sulfate. Enzyme
concentrations were in the range 0.5–1 mg ml1. All samples
were filtrated and degassed. Temperatures were scanned in the
range 10–80C with a gradient of 1C min1. To calculate the
heat capacities the concentrations and molecular weights were
given for the dimers. All measurements were collected using a
CSC Nano-Differential Scanning Calorimeter III (N-DSC III)
with the pressure kept constant at 304 kPa. All data were
analyzed in NanoAnalyze 3.6 (TA Instruments, New Castle,
Delaware, USA).
2.4. Crystallization conditions
tOXA-163, tOXA-181 and tOXA-245 were used for crys-
tallization experiments. Conditions for tOXA-163 (9 mg ml1)
and tOXA-181 (11 mg ml1) were identified from screening
284 in-house stochastic crystallization conditions, whereas the
conditions for tOXA-245 (3 mg ml1) were based on the
conditions for the tOXA-48 homologue. Ethanediol was
added to the crystallization condition at 17, 20 and 25% to
cryoprotect tOXA-163, tOXA-181 and tOXA-245, respec-
tively, prior to flash-cooling the crystals in liquid nitrogen.
Crystallization information is summarized in Table 1.
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Table 2
X-ray data-collection and processing statistics for tOXA-163, tOXA-181 and tOXA-245.
Values in parentheses are for the outer resolution shell.
tOXA-163 tOXA-181 tOXA-245
Diffraction source BL14.1, BESSY BL14.1, BESSY BL14.1, BESSY
Wavelength (Å) 0.918409 0.918409 0.918409
Temperature (K) 100 100 100
Detector PILATUS 6M PILATUS 6M PILATUS 6M
Crystal-to-detector distance (mm) 293.51 426.55 371.19
Rotation range per image () 0.1 0.1 0.1
Total rotation range () 200 120 200
Exposure time per image (s) 0.4 0.3 0.3
Space group P6522 P62 P21
a, b, c (Å) 121.92, 121.92, 160.43 143.93, 143.93, 53.543 64.16, 108.72, 83.68
, ,  () 90, 90, 120 90, 90, 120 90, 102.39, 90
Mosaicity () 0.12 0.08 0.13
Resolution range (Å) 24.49–2.07 (2.14–2.07) 35.98–2.05 (2.12–2.05) 41.06–2.20 (2.28–2.20)
Total No. of reflections 476104 (48568) 258749 (26225) 211084 (21915)
No. of unique reflections 43401 (4244) 40027 (3911) 56510 (5674)
Completeness (%) 99.90 (100.00) 99.55 (99.21) 99.25 (99.95)
Multiplicity 11.0 (11.4) 6.5 (6.6) 3.7 (3.9)
hI/(I)i 12.66 (2.98) 13.19 (2.27) 11.15 (3.63)
Rmeas 0.1614 (0.8966) 0.08461 (0.8693) 0.0954 (0.387)
Overall B factor from Wilson plot (Å2) 24.49 29.65 29.30
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2.5. X-ray data collection and processing
X-ray diffraction data were collected on BL14.1 operated
by the Helmholtz-Zentrum Berlin (HZB) at the BESSY II
electron-storage ring (Berlin-Adlershof, Germany; Mueller et
al., 2015). Images were indexed and integrated using XDS
(Kabsch, 2010) and were merged and scaled using AIMLESS
(Evans & Murshudov, 2013). 5% of reflections were used for
cross-validation for tOXA-163 and tOXA-181, whereas 2%
were used for tOXA-245. X-ray data-collection and processing
statistics are summarized in Table 2.
2.6. Structure solution and refinement
The structures were solved using Phaser (McCoy et al.,
2007) with one monomer of OXA-48 (PDB entry 3hbr;
Docquier et al., 2009) as the search model. Refinement was
carried out using phenix.refine (Afonine et al., 2012), with
individual isotropic B factors and torsion-angle NCS
restraints. Models were inspected and manually modified
using Coot (Emsley et al., 2010). For the final refinement, TLS
parameters were refined and refinement weights were opti-
mized. Refinement statistics are summarized in Table 3.
Interactions within each protein were evaluated using the
Protein Interactions Calculator (PIC; Tina et al., 2007) and the
Protein Interfaces, Surfaces and Assemblies service PISA at
the European Bioinformatics Institute (http://www.ebi.ac.uk/
pdbe/prot_int/pistart.html; Krissinel & Henrick, 2007). Figures
were prepared using PyMOL (v1.8; Schrödinger).
3. Results and discussion
3.1. Enzyme production and enzyme kinetics
In this paper two gene constructs were used: either with
native leader sequences followed by periplasmic purification
(nOXA-181 and nOXA-245) or His-TEV gene constructs
(tOXA-163, tOXA-181 and tOXA.245), where the His tag was
cleaved with TEV protease. All gene constructs were
expressed in E. coli. The highest yield was obtained for tOXA-
181, with up to 55 mg of enzyme per litre in BL21 (DE3)
pLysS cells in TB medium. tOXA-163 was expressed in BL21
(DE3) pLysS cells in TB medium, whereas nOXA-181,
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Figure 1
Sequence alignment of OXA-48, OXA-163, OXA-181 and OXA-245. The conserved active-site motifs are marked in blue. Secondary-structure elements
are from the crystal structures of tOXA-48 (top; PDB entry 5dtk) and tOXA-245 (bottom; PDB entry 5oe2). The red triangle denotes the end of the
signal peptide. The red star denotes the active-site serine. Grey stars indicate residues with alternate conformations in the crystal structure of OXA-48.
This figure was prepared using ESPript 3.0 (Robert & Gouet, 2014).
Table 3
Refinement statistics for tOXA-163, tOXA-181 and tOXA-245.
Values in parentheses are for the outer shell.
tOXA-163 tOXA-181 tOXA-245






Completeness (%) 99.90 (100.00) 99.55 (99.21) 99.25 (99.95)
No. of reflections
Working set 43401 (4244) 39856 (3913) 56501 (5674)
Test set 2186 (222) 1971 (165) 1290 (129)
Final Rcryst 0.1456 (0.1821) 0.2034 (0.3398) 0.1951 (0.2304)
Final Rfree 0.1870 (0.2014) 0.2418 (0.4248) 0.2307 (0.2924)
No. of non-H atoms
Protein 3975 3956 7944
Ligands 17 6 3
Water 367 476 536
Total 4359 4438 8483
R.m.s. deviations
Bonds (Å) 0.014 0.003 0.004
Angles () 1.38 0.54 0.86
Average B factors (Å2)
Overall 32.84 37.78 39.04
Protein 31.88 36.68 38.87
Ligands 54.98 76.17 25.01
Water 42.28 46.40 41.65
Ramachandran plot
Most favoured (%) 97.22 97.89 97.5
Allowed (%) 2.78 2.11 2.5
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nOXA-245 and tOXA-245 were expressed in BL21 STAR
(DE3) pRARE cells in ZYP5052 autoinduction medium.
The substitutions in the protein sequence for OXA-181 and
OXA-245 (Fig. 1) are located away from the active-site resi-
dues (Fig. 3), and none of the conserved motifs 70STFK73,
118SVV120 or 208KTG210 appear to be influenced. However, it is
well known that modifications of distal sites may influence
enzyme activity (Guarnera & Berezovsky, 2016), so we enzy-
matically characterized nOXA-181 and nOXA-245 and
compared our results with the reported values for OXA-48
(Lund et al., 2016; Docquier et al., 2009; Poirel et al., 2004) and
OXA-163 (Poirel et al., 2011). We tested the substrates
ampicillin, ceftazidime, ertapenem, imipenem and mero-
penem. Both enzymes showed activity against all of the
substrates (Table 4); however, ceftazidime was a poor
substrate. In summary, the substitutions in nOXA-181 and
nOXA-245 did not significantly change the enzymatic char-
acteristics compared with OXA-48. OXA-163, however, has
an overall lower catalytic efficiency, but much higher turnover
rates for ceftazidime.
3.2. Thermostability analysis by differential scanning
calorimetry
Even though the enzyme kinetics did not reveal any
significant functional changes between nOXA-181 and
nOXA-245, an investigation of thermostability properties
could still reveal differences. We determined the midpoint
melting temperatures (Tm) for tOXA-48, tOXA-163, tOXA-
181 and tOXA-245 by differential scanning calorimetry
(DSC). Since all four enzymes are dimers according to inter-
action analysis of the crystal structures, with 10–20% of the
surface buried up on dimerization (Krissinel & Henrick, 2007),
and gel-filtration experiments of OXA-48 indicate dimer
formation (data not shown), the curves were fitted with the
molecular weights and concentrations of the dimers. The
recorded melting curves (Fig. 2) and their fit to the two-state
model (Supplementary Fig. S1) indicate that all four enzymes
unfold via a two-state transition without a stable intermediate,
like many other dimeric proteins (Neet & Timm, 1994).
tOXA-163 and tOXA-181 have a broader melting curves than
tOXA-48 and tOXA-245 (Fig. 2) possibly owing to lower
protein concentrations, nonhomogeneous samples or minor
impurities. Still, we found tOXA-163 to be the least stable of
the OXA-48-like enzymes, with a Tm of 49.40
C compared
with the other OXA-48-like enzymes with midpoint melting
temperatures of 55.3C (tOXA-48), 52.6C (tOXA-181) and
55.8C (tOXA-245) (Table 5, Fig. 2).
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Figure 2
Differential scanning calorimetry curves for tOXA-48 (red), tOXA-163
(blue), tOXA-181 (purple) and tOXA-245 (green) showing that tOXA-
245 and tOXA-48 have the highest melting temperatures, whereas tOXA-
181 and tOXA-163 have lower melting points.
Table 4
Kinetic parameters of purified nOXA-181 and nOXA-245 with standard errors from three replicates, showing similar hydrolytic properties compared
with nOXA-48.
Results for nOXA-48 and OXA-163 are included for reference (Lund et al., 2016; Poirel et al., 2011).
Penicillin Cephalosporin Carbapenems
Ampicillin Ceftazidime Ertapenem Imipenem Meropenem
nOXA-181
Km (mM) 23  5 170  90 900  300 17  4 0.3  0.1
kcat (s
1) 2100  200 0.7  0.2 1.6  0.3 5.1  0.4 0.013  0.01
kcat/Km (mM
1 s1) 91 0.004 0.002 0.3 0.04
nOXA-245
Km (mM) 35  13 110  80 80  20 11  1 2  0.8
kcat (s
1) 1200  200 0.3  0.1 0.29  0.03 4.4  0.2 0.11  0.01
kcat/Km (mM
1 s1) 34 0.003 0.004 0.40 0.05
nOXA-48†
Km (mM) 150 5100 100 7.9 1
kcat (s
1) 560 4 0.13 4.5 0.1
kcat/Km (mM
1 s1) 4 0.0008 0.001 0.6 0.1
OXA-163‡
Km (mM) 320 >2000 150 530 2200
kcat (s
1) 25 200 0.01 0.03 0.07
kcat/Km (mM
1 s1) 0.1 <0.1 0.00007 0.00006 0.00003
† The enzyme kinetic parameters for nOXA-48 with ampicillin, imipenem and meropenem are from Lund et al. (2016), those with ceftazidime are from Poirel et al. (2004) and those with
ertapenem are from Docquier et al. (2009). ‡ The enzyme kinetic parameters for OXA-163 are from Poirel et al. (2011).
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3.3. New crystal structures of tOXA-181 and tOXA-245,
and a new tOXA-163 crystal form resolved by X-ray
crystallography
We present the first crystal structures of the OXA-48-like
-lactamases tOXA-181 and tOXA-245 and a new crystal
form of tOXA-163. The new crystal form of tOXA-163
belonged to space group P6522 and diffracted to 2.07 Å
resolution, with Rcryst and Rfree values of 0.15 and 0.19,
respectively. The tOXA-181 enzyme crystallized in space
group P62 and diffracted to 2.05 Å resolution, with Rcryst and
Rfree values of 0.20 and 0.24, respectively. Finally, tOXA-245
crystallized in space group P21 and diffracted to 2.20 Å reso-
lution, with refined Rcryst and Rfree values of 0.20 and 0.23,
respectively. Gly22 from the TEV site is absent in all struc-
tures and Lys23 is missing in all tOXA-181 and tOXA-245
chains, but otherwise all residues are included in the final PDB
models. The asymmetric unit of the new crystal structures are
different (Fig. 3): tOXA-163 and tOXA-181 have a dimer in
the asymmetric unit, corresponding to the expected biological
assembly, while tOXA-245 has two dimers in the asymmetric
unit. An interesting feature is the chloride ions that are
observed to bridge two arginines at the dimer interface: one
arginine from each monomer in all three new OXA structures.
Other class D -lactamases such as OXA-10 are known to
have a cation-mediated dimerization with a histidine acid in
the same position binding to a divalent cation such as cobalt,
copper or zinc (Paetzel et al., 2000; Danel et al., 2001).
As expected from the sequence alignment (Fig. 1), the new
structures show a close resemblance in their tertiary structure.
The mutations are all on the surface of the proteins and the
dimer interface is undisturbed. When all monomers of the new
structures are compared against each other (tOXA-163,
tOXA-181 and tOXA-245), the different chains in the asym-
metric units have r.m.s.d. values for C atoms in the range 0.3–
0.6 Å as calculated by the protein structure-similarity service
PDBeFold at the European Bioinformatics Institute (Krissinel
& Henrick, 2004).
3.4. The increased flexibility necessary for cephalosporin
hydrolysis makes OXA-163 less stable
OXA-163 differs from OXA-48 by an S212D substitution
and a four-amino-acid deletion corresponding to Arg214,
Ile215, Glu216 and Pro217 in OXA-48. Crystal structures of
OXA-163 have previously been reported (PDB entries 4s2l,
4s2m and 5har; Stojanoski et al., 2015, 2016); however, we
report a new space group and unit cell for our tOXA-163
structure, similar to a crystal form reported for a laboratory
mutant of OXA-48 (PDB entry 5hap; Stojanoski et al., 2016)
crystallized from similar conditions. Comparing our tOXA-
163 structure with another OXA-163 structure (PDB entry
4s2l) reveals perturbations that are localized primarily to polar
surface residues, and there are two molecules in the asym-
metric unit (Fig. 3). The r.m.s.d. for C atoms in one tOXA-163
chain compared with existing OXA-163 structures are: 0.32–
0.43 Å for PDB entry 4s2l, 0.52–0.67 Å for PDB entry 4s2m
and 0.32–0.46 Å for PDB entry 5har.
For tOXA-163, shortening the loop (Fig. 4) connecting 7
to 8 opens up access to the active site, allowing the binding
of bulkier groups, as found in, for example, cephalosporins
(Stojanoski et al., 2015). From the enzymatic characterization
(Table 4) it was clear that this structural change increases the
catalytic turnover for the cephalosporin ceftazidime dramati-
cally, but the carbapenemase enzyme activity is nearly abol-
ished. The DSC results shows that tOXA-163 had a 5.9C
lower melting temperature compared with tOXA-48 (Table 5)
and the structure shows that the deletion of residues 214–217
in tOXA-163 disrupts two ionic bonds, Arg214–Asp159
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Figure 3
The quaternary structures of tOXA-163 (a), tOXA-181 (b) and tOXA-245 (c) reveal biological dimers with buried chloride ions in the dimer interface
(grey). For OXA-245 there are two dimers in the asymmetric unit (one is shown). Active-site motifs are coloured in red and residues involved in
substitutions are shown in blue and marked with asterisks.
Table 5
Midpoint melting temperatures (Tm) determined by differential scanning
calorimetry for tOXA-48, tOXA-163, tOXA-181 and tOXA-245.
Tm values are given as the mean with standard deviations from duplicate
experiments performed in 50 mM HEPES pH 7.0 with 50 mM potassium
sulfate. The apparent unfolding enthalpies (H) with standard deviations
were calculated for a two-state model with the enzymes modelled as dimers.
Tm (
C) H (kJ mol1)
tOXA-48 55.3  0.2 1500  200
tOXA-163 49.4  0.1 1280  50
tOXA-181 52.6  0.1 1400  300
tOXA-245 55.8  0.1 1700  100
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(2.9 Å) and Glu216–Lys218 (2.4 Å), that are found in both
tOXA-181 and tOXA-245 (Figs. 4a, 4b and 4c). The effect of
the S212D mutation in OXA-163 seems to partially compen-
sate for the loss of two ionic bonds by forming two hydrogen
bonds from the Asp212 side chain to the main-chain N atoms
of residue 218 and 219 rather than one as found in tOXA-181
and tOXA-245 (Figs. 4a, 4b and 4c). For OXA-163 it appears
that the destabilization of the structure allows greater flex-
ibility and easier access to the active site, facilitating the
hydrolysis of bulky substrates (Simakov et al., 2017).
3.5. OXA-181 reveals decreased thermostability
The OXA-181 enzyme differs from OXA-48 by four
substitutions: T104A, N110D, E168Q and S171A. Our new
structure was resolved to 2.05 Å resolution in space group P62,
with two molecules in the asymmetric unit (Fig. 3). The
tOXA-181 structure has very similar unit-cell parameters to
some of the crystals of the homologues OXA-48 (PDB entry
4s2k; King et al., 2015) and OXA-232 (PDB entry 5hfo;
P. Retailleau, S. Oueslati, C. Cisse, P. Nordmann, T. Naas &
B. Iorga, unpublished work), but the tOXA-181 crystals grew
from different crystallization conditions.
The nOXA-181 enzyme has the highest activity against
ampicillin of the tested OXAs and has some activity against
ceftazidime (Table 4). The activity of nOXA-181 against the
carbapenems is lower than that of nOXA-48; however, these
in vitro results are not reflected in bacterial cells, where
OXA-48 and OXA-181 have very similar hydrolytic profiles
(Potron, Nordmann et al., 2011).
For tOXA-181 the thermal stability was reduced by 2.7C
compared with tOXA-48 (Table 5) and this could be attributed
to changes in the tertiary structure. The N110D mutation in
tOXA-181 introduces an ionic bond from Asp110 to His90,
research communications
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Figure 4
The substitutions in tOXA-163 (green), tOXA-181 (cyan) and tOXA-245 (magenta). (a), (b) and (c) show the S212D substitution and the deletion of
residues 214–217 in tOXA-163 which disrupt two ionic bonds. (e), ( f ) and (g) show the N110D substitution in OXA-181; the aspartic acid forms an ionic
bond to His90, which disrupts the Asp88-His90-Glu89 network. (i), (j) and (k) show the E125Y substitution in tOXA-245, where the loss of an ionic bond
to Arg128 is compensated by – stacking from Tyr125 to both Phe93 and Phe126. (d), (h) and (l) show superpositions of tOXA-163 (green), tOXA-181
(cyan) and tOXA-245 (magenta) for comparison of the three structures.
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causing the His90 residue to shift significantly. This disrupts
the ionic network Asp88-His90-Glu89 as found in OXA-48
(not shown), tOXA-163 and tOXA-245 (Figs. 4d, 4e and 4f).
The other OXA-181 mutations T104A and S171A decrease
the overall polarity of the surface, which is likely to make the
protein less stable (Vogt et al., 1997; Michetti et al., 2017), thus
explaining the lower thermal stability of tOXA-181 compared
with tOXA-48.
3.6. A new crystal structure of tOXA-245 uncovers a
stabilizing aromatic network
OXA-245 differs from OXA-48 by the single substitution
E125Y. The tOXA-245 crystal structure belonged to space
group P21 with four molecules in the asymmetric unit and was
refined to 2.20 Å resolution. tOXA-245 crystallized with
similar unit-cell parameters to another crystal form of
OXA-48 (PDB entry 3hbr).
In our substrate-hydrolysis experiments, nOXA-245 shows
the same behaviour as nOXA-181, with higher activity against
ampicillin compared with nOXA-48, some activity against
ceftazidime and weaker carbapenemase activity than nOXA-
48, except for the carbapenem ertapenem, towards which
nOXA-245 had the highest activity of the tested OXAs
(Table 4). This behaviour is consistent with the antibiotic-
susceptibility profile reported previously (Oteo et al., 2013).
tOXA-245 had an increased overall stability of 0.5C
compared with tOXA-48 (Table 5) and only has the E125Y
substitution. This stabilization is surprising, since Glu125 in
the other structures forms an ionic bond to Arg129 and a
hydrogen bond to Gln129. However, in the tOXA-245 crystal
structure Tyr125 makes a hydrogen bond to Gln129 with the
phenolic hydroxyl group and – stacking interactions with
Phe126 (6.0 Å between the ring centroids) and Phe93 (6.5 Å
between the ring centroids). The – stacking from Phe93 to
Phe126 and the hydrogen bond from the Gln129 amide N
atom to the Tyr125 hydroxyl group may compensate for the
loss of the ionic bond (Figs. 4g, 4h and 4i), and thus stabilize
the protein and explain the observed 0.5C increase in overall
stability. – stacking has been reported in the literature to
enhance the overall thermostability (Karlström et al., 2006).
4. Conclusion
Overall, it appears that the changes in the nOXA-181 and
nOXA-245 protein sequences are well tolerated, giving a
similar hydrolytic spectrum compared with nOXA-48. In
overall thermal stability, tOXA-163 was the least stable OXA-
48-like enzyme, with a melting temperature reduced by 5.9C
compared with tOXA-48. Based on the crystal structures, we
hypothesize that this decrease is caused by two broken salt
bridges (Glu126–Arg128 and Glu159–Arg214) and a more
accessible active site compared with the three other OXA
enzymes. The tOXA-181 enzyme has a 2.7C lower melting
point compared with tOXA-48, possibly owing to one broken
ionic interaction in the Asp88-His90-Glu89 network caused by
the shift of His90 towards Asp110, combined with an overall
decrease in surface polarity. Finally, tOXA-245 was most
similar to tOXA-48, with an increased Tm of 0.5
C, and this
increase could arise from one additional hydrogen bond
(Tyr125–Asn129) and the – aromatic stacking network with
Phe93-Tyr125-Phe126 compensating for the loss of the
Glu125–Arg128 salt bridge.
From these observations, we speculate that a bacterium
carrying a serine -lactamase already has an advantage in
-lactam resistance, that the differences in the sequences of
OXA-181 and OXA-245 depend on the original host
organism, and that these differences are tolerated as long as
there is no interference with substrate hydrolysis.
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Poirel, L., Castanheira, M., Carrër, A., Rodriguez, C. P., Jones, R. N.,
Smayevsky, J. & Nordmann, P. (2011). Antimicrob. Agents
Chemother. 55, 2546–2551.
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Supporting information  
Table S1 Macromolecule production information for the cloning and production of OXA-
163,OXA-181 and OXA-245. Italic nucleotides   
Source organism Klebsiella pneumoniae 
DNA source  Genomic DNA  
 
Native construct with signal 
peptide: 




























Cloning vector pDEST17 
Expression vector pDEST17 
Expression host E. coli BL21 (DE3) STAR pRARE 












































































a The nucleotides in the TEV protease cleavage site sequence is in italics. Underlined residues in the amino acid 
sequence are cleaved off by signal peptide peptidases in transport to the periplasm for the native construct or by 
an in-house TEV-protease during purification for the His-tagged construct.  
b The gene for OXA-163 was synthesized with optimized codon usage and subcloned into the expression vector. 
 





Figure S1 Differential scanning calorimetry curves (red) for (A) OXA-48, (B) OXA-163, (C) OXA-
181 and (D) OXA-245 with the theoretical two-state model fitted (blue) for the respective dimers to 
calculate the ΔH of unfolding.  
 
